# The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis

> **NCT06393972** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Glucocorticoid Resistant ICIs-related Myocarditis

## Interventions

- **DRUG:** Tofacitinib 5 MG BID

## Key facts

- **NCT ID:** NCT06393972
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06393972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06393972, "The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06393972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*